At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IGA Voya Global Advantage and Premium Opportunity Fund
Market Closed 12-12 16:00:00 EST
9.77
+0.02
+0.21%
盘后9.77
+0.000.00%
16:10 EST
High9.78Low9.72Vol44.24K
Open9.77D1 Closing9.75Amplitude0.64%
Mkt Cap149.89MTradable Cap149.89MTotal Shares15.34M
T/O431.14KT/O Rate0.29%Tradable Shares15.34M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Saviynt Raises $700M at Approximately $3B Valuation in KKR-Led Round to Establish Identity Security as the Foundation for the AI Era
Dow Jones  ·  12-09
Press Release: Saviynt Raises $700M at Approximately $3B Valuation in KKR-Led Round to Establish Identity Security as the Foundation for the AI Era
Voya Financial Inc. announces $0.085 per share dividend for Voya Global Advantage and Premium Opportunity Fund
Reuters  ·  11-18
Voya Financial Inc. announces $0.085 per share dividend for Voya Global Advantage and Premium Opportunity Fund
Press Release: Voya Global Advantage and Premium Opportunity Fund & Voya Infrastructure, Industrials and Materials Fund Announces Payment of Monthly Distribution
Dow Jones  ·  11-18
Press Release: Voya Global Advantage and Premium Opportunity Fund & Voya Infrastructure, Industrials and Materials Fund Announces Payment of Monthly Distribution
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
GlobeNewswire  ·  11-04
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
GlobeNewswire  ·  10-30
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study
GlobeNewswire  ·  10-28
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
GlobeNewswire  ·  10-24
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Press Release: Voya Equity Closed End Funds Declare Distributions
Dow Jones  ·  10-16
Press Release: Voya Equity Closed End Funds Declare Distributions
Bitcoin Depot and IGA Partner to Bring Bitcoin Access to Neighborhood Grocery Stores
GlobeNewswire  ·  10-14
Bitcoin Depot and IGA Partner to Bring Bitcoin Access to Neighborhood Grocery Stores
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
GlobeNewswire  ·  09-17
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
GlobeNewswire  ·  09-17
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION
Dow Jones  ·  09-16
Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION
Voya Global Advantage & Premium Opportunity Fund Files Initial Beneficial Ownership Statement; Mark R. Wetzel Named as Director
Reuters  ·  09-11
Voya Global Advantage & Premium Opportunity Fund Files Initial Beneficial Ownership Statement; Mark R. Wetzel Named as Director
Press Release: Voya Equity Closed End Funds Declare Distributions
Dow Jones  ·  08-16
Press Release: Voya Equity Closed End Funds Declare Distributions
Voya Financial Inc. Announces New Dividend; Voya Global Advantage and Premium Opportunity Fund to Pay $0.085 Per Share, Voya Infrastructure, Industrials and Materials Fund to Pay $0.100 Per Share
Reuters  ·  08-16
Voya Financial Inc. Announces New Dividend; Voya Global Advantage and Premium Opportunity Fund to Pay $0.085 Per Share, Voya Infrastructure, Industrials and Materials Fund to Pay $0.100 Per Share
Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION
Dow Jones  ·  08-16
Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION
Quoin Pharmaceuticals Provides Product Portfolio Update
GlobeNewswire  ·  07-29
Quoin Pharmaceuticals Provides Product Portfolio Update
Press Release: Voya Global Advantage and Premium Opportunity Fund & Voya Infrastructure, Industrials and Materials Fund Announces Payment of Monthly Distribution
Dow Jones  ·  07-16
Press Release: Voya Global Advantage and Premium Opportunity Fund & Voya Infrastructure, Industrials and Materials Fund Announces Payment of Monthly Distribution
Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION
Dow Jones  ·  06-17
Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION
Voya Global Advantage And Premium Opportunity Fund Releases June 2025 Distribution Report
Reuters  ·  06-16
Voya Global Advantage And Premium Opportunity Fund Releases June 2025 Distribution Report

Introduction

Company Name.
Voya Global Advantage and Premium Opportunity Fund
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Voya Global Advantage and Premium Opportunity Fund is a closed-ended equity mutual fund launched by Voya Investment Management LLC. The fund is co-managed by Voya Investments, LLC, Voya Investment Management Co. LLC, and NNIP Advisors B.V. It invests in public equity markets across the globe. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in value stocks of companies across all market capitalizations. The fund also invests through index call options on selected indices, equities, and/or exchange-traded funds. It employs fundamental analysis with a bottom-up stock picking approach and a proprietary discounted cash flow valuation model, focusing on such factors as sales, margins, and capital use to create its portfolio. The fund benchmarks the performance of its portfolio against the MSCI World Index. It was formerly known as ING Global Advantage and Premium Opportunity Fund. Voya Global Advantage and Premium Opportunity Fund was formed on July 7, 2005 and is domiciled in the United States.
Issue price:
--